The funding highlights how service robotics is shifting from niche deployments to scaled commercial use across global markets
Updated
April 24, 2026 2:26 PM
An autonomous service robot with a cat face design standing inside a McDonalds restaurant. PHOTO: ADOBE STOCK
Pudu Robotics, a Shenzhen-based startup building robots for commercial environments, has raised nearly US$150 million in a new funding round, pushing its valuation past US$1.5 billion. The raise brings the company’s total funding to more than US$300 million.
The company focuses on service robotics across sectors such as delivery, cleaning and industrial logistics. Its systems are used in places like retail stores, warehouses and public venues where routine tasks can be automated. Over time, Pudu has expanded from single-purpose machines to a broader portfolio that combines hardware with AI-driven navigation and coordination.
The funding is expected to support several areas of growth. These include further development of its AI systems, expansion of its product range and continued international rollout. The company also plans to invest in manufacturing and supply chain capacity, suggesting a focus on scaling production alongside demand.
Pudu’s recent growth provides some context for the raise. The company reported a doubling of revenue by 2025, with its cleaning robots now accounting for the majority of its business. Its industrial delivery robots have also seen early traction, with thousands of units deployed within a year of launch.
Its products are already in use with large global retailers including Carrefour, Walmart and EDEKA. Industry estimates place Pudu among the largest players in commercial service robotics, with a leading share of the global market.
Technically, the company develops much of its core stack in-house, including navigation systems, multi-robot coordination software and motion control. This allows its robots to operate in complex real-world environments where multiple machines need to move and work together.
“This financial milestone is a powerful confirmation of Pudu’s industry leadership, the strength of its products and technology, its global brand, and its commercial infrastructure. With the support of our strategic investors and industry partners, Pudu will continue to push the boundaries of embedded AI and business service robotics. We remain committed to innovating with an inventor’s spirit and leveraging a global vision to accelerate robot adoption, thereby elevating the industry to new heights in the global value chain”. said Felix Zhang, founder and CEO of Pudu Robotics.
The funding round points to a broader shift in the sector. As service robotics moves from pilot deployments to wider adoption, companies are increasingly being judged on their ability to scale production and operate across markets, not just on the novelty of their technology.
Keep Reading
A new bet on early heart failure detection and why women’s health is at the center.
Updated
January 8, 2026 6:28 PM
A doctor holding an artificial heart model. PHOTO: ADOBE STOCK
Heart disease does not always announce itself clearly, especially in women. Many of the symptoms are ordinary, including fatigue, shortness of breath and swelling. These signs are frequently dismissed or explained away. As a result, many women are diagnosed late, when treatment options are narrower and outcomes are worse. That diagnostic gap is the context behind a recent investment involving Ultromics and the American Heart Association’s Go Red for Women Venture Fund.
Ultromics is a health technology company that uses artificial intelligence to help doctors spot early signs of heart failure from routine heart scans. It has received a strategic investment from the American Heart Association’s Go Red for Women Venture Fund.
The focus of the investment is a long-standing blind spot in cardiac care. Heart failure with preserved ejection fraction, or HFpEF, affects millions of people worldwide, with women disproportionately impacted. It is one of the most common forms of heart failure, yet also one of the hardest to diagnose. Studies even show women are twice as likely as men to develop the condition and around 64% of cases go undiagnosed in routine clinical practice.
Ultromics works with a tool most patients already experience during heart care: the echocardiogram. There is no new scan and no added burden for patients. Its software analyzes standard heart ultrasound images and looks for subtle patterns that point to early heart failure. The goal is clarity. Give clinicians better signals earlier, before the disease advances.
“Heart failure with preserved ejection fraction is one of the most complex and overlooked diseases in cardiology. For too long, clinicians have been expected to diagnose it using tools that weren't built to detect it and as a result, many patients are identified too late,” said Ross Upton, PhD, CEO and Founder of Ultromics. “By augmenting physicians' decision making with EchoGo, we can help them recognize disease at an earlier stage and treat it more effectively.”
The stakes are high. Research suggests women are twice as likely as men to develop the condition and that a majority of cases are missed in routine clinical practice. That delay matters. New therapies can reduce hospitalizations and improve survival, but only if patients are diagnosed in time.
This is why early detection has become a priority for mission-driven investors. “Closing the diagnostic gap by recognizing disease before irreversible damage occurs is critical to improving health for women—and everyone,” said Tracy Warren, Senior Managing Director, Go Red for Women Venture Fund. “We are gratified to see technologies, such as this one, that are accepted by leading institutions as advances in the field of cardiovascular diagnostics. That's the kind of progress our fund was created to accelerate.”
Ultromics’ platform is already cleared by regulators for clinical use and is being deployed in hospitals across the US and UK. The company says its technology has analyzed hundreds of thousands of heart scans, helping clinicians reach clearer conclusions when traditional methods fall short.
Taken together, the investment reflects a broader shift in healthcare. Attention is shifting earlier—toward detection instead of reaction. Toward tools that fit into existing care rather than complicate it. In this case, the funding is not about introducing something new into the system. It is about seeing what has long been missed—and doing so in time.